If your employer covers a weight-loss drug today, the document that tells you whether that continues next year is the summary of benefits and coverage you will get during open enrollment. For a meaningful minority of workers, it will read differently than last year's.
Two benefits surveys point the same direction. A Business Group on Health survey of 105 large employer members, fielded in February and March 2026, found that 67 percent currently cover GLP-1 medications for weight management. Of those, only 72 percent said they were likely to maintain that coverage in 2027, meaning roughly one in ten expects to drop it.
